Neurelis

CompanyUnited StatesFounded 2007

Wikidata

Neurelis develops 2 assets, the furthest approved (Valtoco in epilepsy). Mostly small molecule acting on GABRA5, GABRA1 and GABRG2; based in the United States, founded in 2007.

2
Assets
Furthest stage
Approved
4
Trials
4
Signals

Pipeline

2
  • Valtoco

    Approved, Small molecule, GABRA5, GABRA1, epilepsy

  • NRL-1049

    Inhibits ROCK2 to stabilize vascular endothelial barriers and reduce vascular leakage.

    Phase 1, Small molecule, ROCK2, cerebral cavernous malformations

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms12
  • Trials5
  • Signals4
  • Similar companies6

Intelligence